Franco Pacini | Academic Influence

Franco Pacini's AcademicInfluence.com Rankings

Franco Pacini

Physics

#1311

World Rank

#2051

Historical Rank

Astrophysics

#103

World Rank

#117

Historical Rank

Astronomy

#227

World Rank

#505

Historical Rank

physics Degrees

Download Badge

Physics

Franco Pacini's Degrees

PhD Astrophysics University of Florence
Masters Physics University of Florence

Why Is Franco Pacini Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Franco Pacini was an Italian astrophysicist and professor at the University of Florence. He carried out research, mostly in High Energy Astrophysics, in Italy, France, United States and at the European Southern Observatory.

(See a Problem?)

Franco Pacini's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. (2009) (7672)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. (2009) (7330)
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. (2006) (2006)
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 (2001) (1576)
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. (2015) (1442)
Medullary thyroid cancer: management guidelines of the American Thyroid Association. (2009) (1214)
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. (1996) (1094)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial (2014) (1090)
Guidelines for diagnosis and therapy of MEN type 1 and type 2. (2001) (1038)
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. (2003) (637)
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. (1999) (595)
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (479)
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. (2008) (478)
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. (2004) (475)
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. (2006) (428)
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial (2017) (406)
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. (2003) (386)
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. (2009) (334)
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. (2006) (330)
Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. (2004) (329)
Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens (2003) (316)
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. (2010) (310)
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. (2001) (296)
Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. (2002) (286)
Decreased Levels of Helper T Cells: A Possible Cause of Immunodeficiency in Pregnancy (1982) (283)
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. (1994) (276)
Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. (1987) (270)
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. (2013) (261)
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. (2001) (258)
American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with (2017) (253)
Definition and management of radioactive iodine-refractory differentiated thyroid cancer. (2014) (247)
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. (2006) (242)
Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. (1992) (242)
Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. (1997) (239)
BRAFV599E Mutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas (2004) (234)
Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. (2011) (234)
RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. (2007) (226)
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. (2010) (207)
Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. (2002) (207)
131I therapy for elevated thyroglobulin levels. (1997) (203)
Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. (2005) (201)
Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. (1996) (199)
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. (2001) (185)
Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? (2016) (182)
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. (2006) (182)
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. (2002) (180)
A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. (2007) (173)
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. (2005) (171)
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. (1996) (170)
Thyroid cancer in children and adolescents (1988) (168)
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (2015) (162)
N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. (2000) (156)
Thyroid function modulates thymic endocrine activity. (1986) (155)
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment (2015) (151)
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. (2001) (151)
Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. (1988) (151)
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. (2008) (150)
Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. (1994) (149)
Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine (1994) (148)
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. (2004) (147)
Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. (1989) (143)
Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies (2018) (139)
Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? (1995) (139)
Thyroid carcinoma in thyrotoxic patients treated by surgery (1988) (133)
Serum thyroglobulin in thyroid carcinoma and other thyroid disorders (1980) (132)
Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. (2008) (128)
Medullary thyroid carcinoma. (2010) (124)
Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. (2008) (123)
DIAGNOSTIC VALUE OF A SINGLE SERUM THYROGLOBULIN DETERMINATION ON AND OFF THYROID SUPPRESSIVE THERAPY IN THE FOLLOW‐UP OF PATIENTS WITH DIFFERENTIATED THYROID CANCER (1985) (123)
RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. (2004) (121)
Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. (2004) (115)
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. (2010) (114)
Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. (2001) (113)
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. (2002) (111)
Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. (1996) (110)
A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). (2011) (108)
Clinical features and therapeutic implication of papillary thyroid microcarcinoma. (2007) (108)
2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer (2012) (102)
Follow-up of differentiated thyroid cancer (2002) (101)
SERUM THYROGLOBULIN CONCENTRATIONS AND 131I WHOLE BODY SCANS IN THE DIAGNOSIS OF METASTASES FROM DIFFERENTIATED THYROID CARCINOMA (AFTER THYROIDECTOMY) (1980) (98)
Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. (1997) (95)
bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. (1996) (93)
Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout (1998) (93)
Decreased suppressor T-lymphocytes in autoimmune thyroid diseases detected by monoclonal antibodies. (1982) (93)
Management of advanced medullary thyroid cancer. (2016) (92)
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. (2009) (91)
Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. (2013) (89)
DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients (2017) (87)
European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer (2012) (85)
Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. (2002) (84)
131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. (2001) (83)
L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. (2008) (82)
Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. (1995) (81)
Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. (1991) (78)
Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. (2008) (78)
The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. (2008) (77)
Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (74)
Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. (2013) (73)
Fine needle aspiration and medullary thyroid carcinoma: the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone. (2013) (72)
Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. (1994) (72)
Human thyroglobulin reference material (CRM 457). 2nd Part: Physicochemical characterization and certification. (1996) (71)
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (71)
Approach to and treatment of differentiated thyroid carcinoma. (2012) (71)
Clinical use of recombinant human TSH in thyroid cancer patients. (2000) (71)
Identification of the Cys634->Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis (1994) (69)
Unsuspected parathyroid cysts diagnosed by measurement of thyroglobulin and parathyroid hormone concentrations in fluid aspirates. (1985) (69)
Interleukin-6 release from human abdominal adipose cells is regulated by thyroid-stimulating hormone: effect of adipocyte differentiation and anatomic depot. (2006) (69)
Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. (2009) (67)
Disappearance Rate of Serum Calcitonin after Total Thyroidectomy for Medullary Thyroid Carcinoma (1994) (66)
Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. (2010) (64)
Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. (2004) (64)
Percutaneous intranodular ethanol injection for treatment of autonomously functioning thyroid nodules. (1992) (63)
Acute exogenous TSH administration stimulates leptin secretion in vivo. (2010) (62)
Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. (1996) (60)
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. (2013) (59)
The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma (2011) (58)
Human thyroglobulin reference material (CRM 457). 1st Part: Assessment of homogeneity, stability and immunoreactivity. (1996) (58)
Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. (2017) (58)
Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index. (2000) (57)
RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. (2001) (57)
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. (2004) (56)
Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas. (1997) (54)
Follicular cell-derived thyroid cancer (2015) (53)
Thyroid consequences of the Chernobyl nuclear accident (1999) (52)
Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population. (2014) (51)
Simian virus 40-like DNA sequences in human papillary thyroid carcinomas (1998) (51)
Serum ghrelin as a marker of atrophic body gastritis in patients with parietal cell antibodies. (2007) (50)
Interference of serum thyroglobulin in the radioassay for serum antithyroglobulin antibodies. (1977) (50)
Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. (2008) (49)
Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions (2012) (49)
Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease. (1999) (48)
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. (2008) (47)
Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study. (2011) (46)
Establishment of a non‐tumorigenic papillary thyroid cell line (FB‐2) carrying the RET/PTC1 rearrangement (2002) (46)
All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. (2005) (46)
Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. (2003) (45)
Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. (1997) (44)
Management of thyroid nodules: a clinicopathological, evidence-based approach (2004) (43)
Effect of hypo- and hyperthyroidism on the balance between helper and suppressor T cells in rats. (1983) (43)
Somatostatin in medullary thyroid cancer. In vitro and in vivo studies (1989) (41)
Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer. (1999) (41)
Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. (2006) (39)
Reference range of serum calcitonin in pediatric population. (2015) (38)
Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series but not in cytological series: evidence for selection bias. (2014) (37)
RET proto-oncogene mutations in thyroid carcinomas: Clinical relevance (2000) (37)
Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. (1994) (37)
Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer. (2005) (36)
Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancer. (2012) (36)
Polyclonal origin of medullary carcinoma of the thyroid in multiple endocrine neoplasia type 2 (1997) (36)
Authors’ Response: A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid Carcinoma (2003) (35)
Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism (2006) (34)
Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene (1997) (34)
Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer. (2011) (33)
clinical practice guidelines Thyroid cancer : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow-up (2010) (33)
Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology (2015) (32)
Bariatric Surgery Reduces Serum Anti-mullerian Hormone Levels in Obese Women With and Without Polycystic Ovarian Syndrome. (2017) (32)
Simian virus 40-like sequences from early and late regions in human thyroid tumors of different histotypes. (2003) (32)
Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer (2019) (32)
Prevalence of parietal cell antibodies in a large cohort of patients with autoimmune thyroiditis. (2010) (32)
IFNγ-Inducible Chemokines Decrease upon Selenomethionine Supplementation in Women with Euthyroid Autoimmune Thyroiditis: Comparison between Two Doses of Selenomethionine (80 or 160 μg) versus Placebo (2015) (31)
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab (2017) (31)
Multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis: Description of a new family (1993) (31)
Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association (2016) (30)
Thyroid microcarcinoma. (2012) (30)
Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization (1982) (29)
Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial. (2014) (29)
Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas (1999) (29)
An Unusual Case of a False-Positive lodine-131 Whole Body Scan in a Patient with Papillary Thyroid Cancer (1988) (28)
Long-term efficacy of modified-release recombinant human thyrotropin augmented radioiodine therapy for benign multinodular goiter: results from a multicenter, international, randomized, placebo-controlled, dose-selection study. (2014) (28)
A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). (2012) (27)
Suppression of Fas Expression and Down-Regulation of Fas Ligand in Highly Aggressive Human Thyroid Carcinoma (2000) (27)
Weight Loss Associated with Bariatric Surgery Does Not Restore Short Telomere Length of Severe Obese Patients After 1 Year (2014) (26)
How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer (2007) (25)
Post-thyroidectomy chronic asthenia: self-deception or disease? (2015) (24)
Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement. (1999) (24)
Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients (2016) (24)
Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thyroid cancer. (2011) (24)
Management of papillary thyroid microcarcinoma: primum non nocere! (2013) (24)
Ultrasound examination using contrast agent and elastosonography in the evaluation of single thyroid nodules: Preliminary results. (2008) (24)
Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. (2005) (23)
RET/PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously revealed by elevated serum thyroglobulin concentration. (2005) (23)
Expression of the Mr 67,000 laminin receptor is an adverse prognostic indicator in human thyroid cancer: an immunohistochemical study. (1996) (23)
Thyroid-thymus interactions during development and aging. (1989) (22)
Thyroid microcarcinoma. (2012) (22)
Long-term strategies for thyroid health monitoring after nuclear accidents: recommendations from an Expert Group convened by IARC. (2018) (22)
Management of Subclinical Hypothyroidism in Pregnancy: A Comment from the Italian Society of Endocrinology and the Italian Thyroid Association to the 2017 American Thyroid Association Guidelines-"The Italian Way". (2018) (22)
Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor (2018) (21)
Expanding indications for recombinant human TSH in thyroid cancer. (2008) (21)
Expression of the ring ligase PRAJA2 in thyroid cancer. (2012) (21)
Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis (2017) (21)
Salmonella brandenburg: a novel cause of acute suppurative thyroiditis. (1993) (21)
Lack of germline A339V mutation in thyroid transcription factor-1 (TITF-1/NKX2.1) gene in familial papillary thyroid cancer (2010) (21)
Thymulin deficiency and low 3,5,3'-triiodothyronine syndrome in infants with low birth weight syndromes. (1987) (21)
The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion. (1999) (21)
Multifocality in Sporadic Medullary Thyroid Carcinoma: An International Multicenter Study. (2016) (20)
Treatment of refractory thyroid cancer with andriamycin (1984) (20)
Telomeres and Thyroid Cancer (2009) (20)
Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. (2009) (18)
Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. (2019) (18)
Impaired ventilatory drive in short-term primary hypothyroidism and its reversal by L-triiodothyronine (1985) (18)
STUDIES OF IMMUNOGLOBULIN SYNTHESIS IN CULTURES OF PERIPHERAL T AND B LYMPHOCYTES: REDUCED T‐SUPPRESSOR CELL ACTIVITY IN GRAVES’DISEASE (1983) (17)
Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC (2018) (17)
Diagnostic, therapeutic and health-care management protocol in thyroid surgery: a position statement of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB) (2016) (17)
Obesity Does Not Modify the Risk of Differentiated Thyroid Cancer in a Cytological Series of Thyroid Nodules (2016) (17)
Identification of a novel subtype of H4-RET rearrangement in a thyroid papillary carcinoma and lymph node metastasis. (2000) (17)
[European consensus on the management of patients with differentiated carcinoma of the thyroid from follicular epithelium]. (2008) (17)
2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? (2021) (17)
HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series (2017) (16)
Changing natural history of differentiated thyroid cancer (2012) (16)
Acute liver injury related to the use of niperotidine. (1997) (16)
Extracellular superoxide dismutase induces mouse embryonic fibroblast proliferative burst, growth arrest, immortalization, and consequent in vivo tumorigenesis. (2014) (16)
Lack of mutations of the telomerase RNA component in familial papillary thyroid cancer with short telomeres. (2012) (16)
Targeted therapy in refractory thyroid cancer: current achievements and limitations. (2011) (16)
The low utility of pretherapy scans in thyroid cancer patients. (2009) (15)
Which patient with thyroid cancer deserves systemic therapy and when? (2017) (15)
New breakpoints in both the H4 and RET genes create a variant of PTC‐1 in a post‐Chernobyl papillary thyroid carcinoma (2000) (15)
131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: Results of a retrospective study (2002) (15)
Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+ T lymphocytes (2018) (15)
Use of Surgical Gamma Probe for the Detection of Lymph Node Metastases in Differentiated Thyroid Cancer (2000) (15)
Observation for newly diagnosed micro-papillary thyroid cancer: is now the time? (2014) (14)
Role of percutaneous ethanol injection in management of nodular lesions of the thyroid gland. (2003) (14)
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (2018) (14)
Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer (2001) (13)
Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) receiving open-label Sorafenib post-progression on the phase III decision trial (2015) (13)
Features and outcome of differentiated thyroid carcinoma associated with Graves’ disease: results of a large, retrospective, multicenter study (2020) (13)
McCune-Albright syndrome with gigantism and hyperprolactinemia (1987) (13)
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy (2020) (13)
Diagnostic, therapeutic and healthcare management protocols in parathyroid surgery: II Consensus Conference of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB) (2014) (12)
Post-surgical follow-up of differentiated thyroid cancer (1995) (12)
MicroRNA expression profile of thyroid nodules in fine-needle aspiration cytology: a confirmatory series (2018) (12)
Recombinant Human Thyroid-Stimulating Hormone: Use in Papillary and Follicular Thyroid Cancer (2007) (12)
Rare diseases in clinical endocrinology: a taxonomic classification system (2015) (12)
Expression of calcitonin gene-related peptide in medullary thyroid cancer (1992) (12)
Thyroid cancer following Chernobyl (1995) (12)
Serum thyroglobulin determinations in the differential diagnosis of congenital hypothyroidism (1984) (11)
Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand. (2013) (11)
Serum thyroglobulin in newborns’ cord blood, in childhood and adolescence: a physiological indicator of thyroidal status (1984) (11)
Diagnostic Value of Circulating microRNA-95 and -190 in the Differential Diagnosis of Thyroid Nodules: A Validation Study in 1000 Consecutive Patients. (2017) (11)
Telomerase and the endocrine system (2011) (11)
Long-term effects of radioiodine in toxic multinodular goitre: thyroid volume, function and autoimmunity. (2020) (11)
Why do we need guidelines for differentiated thyroid cancer? (2006) (10)
Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma (1994) (10)
Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma (2016) (10)
Where do we stand with targeted therapy of refractory thyroid cancer?--Utility of RECIST criteria. (2008) (9)
Cyclic Cushing’s disease with paradoxical response to dexamethasone (2005) (9)
Serum tissue polypeptide antigen (TPA) in thyroid cancer (1984) (9)
Prognostic and predictive factors correlated with treatment outcomes for radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) patients receiving Sorafenib or placebo on the phase III decision trial (2015) (9)
Should familial disease be considered as a negative prognostic factor in micropapillary thyroid carcinoma? (2019) (9)
[Thyroid carcinoma in a thyroglossal duct cyst: tumor resection alone or a total thyroidectomy?]. (1998) (8)
Targeted therapy in radioiodine refractory thyroid cancer. (2009) (8)
Serum ghrelin levels in growth hormone-sufficient and growth hormone-deficient patients during growth hormone-releasing hormone plus arginine test (2009) (8)
Variants in MCT10 protein do not affect FT3 levels in athyreotic patients (2019) (8)
Alterations of the FSH and LH receptor genes and evaluation of sperm ultrastructure in men with idiopathic hypergonadotropic hypogonadism (2013) (8)
Anaplastic thyroid-carcinoma - a retrospective clinical and immunohistochemical study. (1994) (8)
rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer (2008) (7)
Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements. (2015) (7)
Prognostic indicators for papillary thyroid carcinoma (2017) (7)
Follow-up of Patients with Differentiated Thyroid Carcinoma (2006) (7)
Radiation and thyroid cancer. (1996) (7)
BROX haploinsufficiency in familial nonmedullary thyroid cancer (2020) (7)
Effects of Acute Recombinant Human TSH on Serum Ghrelin Levels (2011) (7)
New insight in the follow-up strategies of differentiated thyroid cancer. (2012) (7)
BINDING OF IMMUNOGLOBULIN‐G FROM PATIENTS WITH THYROID AUTOIMMUNE DISEASE TO NORMAL T LYMPHOCYTES (1983) (7)
Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses (2016) (6)
Percutaneous ethanol injection: what is its role in the management of nodular lesions of endocrine glands? (1995) (6)
Circulating Neuron-Specific Enolase in Medullary Thyroid Cancer (1986) (5)
Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective case–control study in an Italian cohort (2018) (5)
Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells (2019) (5)
VALIDATION OF AMERICAN THYROID ASSOCIATION ULTRASOUND RISK-ADAPTED APPROACH FOR REPEATING CYTOLOGY IN BENIGN THYROID NODULES. (2020) (5)
Thyroid Health Monitoring After Nuclear Accidents : IARC Expert Group on Thyroid Health Monitoring After Nuclear Accidents (2018) (5)
Biology and Clinical Application of the Ms Gene (2003) (5)
Radiation-induced thyroid diseases (2011) (5)
Long-Term Clinical Outcome in Familial and Sporadic Papillary Thyroid Carcinoma (2020) (5)
Thyroid Nodule and Differentiated Thyroid Cancer Guidelines (2010) (5)
How Far Should We Go in the Search and Treatment of Recurrent or Persistent Lymph Node Metastases during Follow-Up of Thyroid Cancer Patients? (2013) (4)
Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer (DTC): The phase III DECISION trial (2014) (4)
Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective (2009) (4)
Multinodular goiter of unusual shape and location. (2007) (4)
Diagnosis of medullary thyroid cancer (2009) (4)
[Prophylactic total thyroidectomy in children and adolescents with genetic mutations in the RET-protooncogene]. (2002) (3)
Prospective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid Cancer (2016) (3)
Screening of thyroid nodules by serum calcitonin measurements: why not? (2012) (3)
Thyroid diseases around Chernobyl: from autoimmune diseases to malignant tumors (2002) (3)
Calcitonin Levels in Thyroid Disease Are Not Affected by Autoimmune Thyroiditis or Differentiated Thyroid Carcinoma (2020) (3)
Papillary thyroid microcarcinoma and active surveillance - Authors' reply. (2016) (3)
Markers of cell-proliferation as prognostic factors in differentiated thyroid-cancer. (1993) (3)
Thymulin Deficiency and Low T3 Syndrome in Infants With Low-Birth-Weight Syndromes (1987) (2)
Multiple endocrine neoplasia type 2 syndromes (MEN 2): Results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes (European Journal of Endocrinology 163 (301-308)) (2010) (2)
The effect of short-term treatment with recombinant human thyroid-stimulating hormones on leydig cell function in men. (2003) (2)
CLINICAL VALIDATION OF IMMUNORADIOMETRIC ASSAY FOR MEASURING SERUM THYROGLOBULIN IN ANTI-THYROGLOBULIN AUTOANTIBODY POSITIVE SERA IN PATIENTS WITH THYROID CANCER (1987) (2)
Diagnostic 131-I whole body scan after total thyroidectomy and thyroid ablation is useless in thyroid cancer patients with undetectable serum thyroglobulin off L-thyroxine therapy (2000) (2)
Radioactive Iodine Activities for Postsurgical Thyroid Ablation: The Lower the Better (2012) (2)
Search for genetic mutations in cytological samples from thyroid nodules as a diagnostic tool: Reality, hope or myth? (2010) (2)
Management of differentiated thyroid cancer of the follicular epithelium (2012) (2)
[Chernobyl 13 years after: consequences for protection of populations]. (1999) (2)
Thyroid function: Optimizing molecular testing in thyroid nodule cytology (2012) (2)
Effect of indomethacin on phytohemagglutinin-stimulated peripheral blood lymphocytes in thyroid autoimmune diseases (1982) (2)
Lack of germline A 339 V mutation in thyroid transcription factor-1 ( TITF-1 / NKX 2 . 1 ) gene in familial papillary thyroid cancer (2010) (2)
Metastatic Medullary and Undifferentiated Thyroid Cancers are not Associated with Elevated Levels of Serum Thyroglobulin (1984) (2)
Humoral markers for thyroid carcinoma. (1986) (2)
Best practice & research clinical endocrinology & metabolism. Thyroid nodules and cancer. Preface. (2008) (2)
BRAF mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer (2008) (2)
Screening of organ-specific autoantibodies in a large cohort of patients with autoimmune thyroid diseases. (2021) (2)
AB1099 CHAGAS DISEASE REACTIVATION IN THE RHEUMATOLOGIC IMMUNOSUPPRESSED PATIENT. IS IT NO LONGER AN ORPHAN DISEASE? (2019) (1)
Thyroid cancer in children and adolescents. (2002) (1)
Does Microscopic Extrathyroidal Extension Confer a Higher Risk of Recurrence in Patients With Well-Differentiated Thyroid Cancer? (2020) (1)
Recombinant Human TSH (rhTSH): Use in Papillary and Follicular Thyroid Cancer (2006) (1)
Serum GH and IGF1 levels in obese patients treated with bariatric surgery (2012) (1)
ROLE OF THE RET PROTO-ONCOGENE IN THYROID CARCINOMA (1997) (1)
Advances in the Diagnosis and Management of Differentiated Thyroid Cancer (2008) (1)
Treatment of patients with primary and secondary adrenal insufficiency with hydrocortisone modified-release (Plenadren®) (2017) (1)
Irradiation, Thyroid and (2004) (1)
Reply to the Letter to the Editor by Sollini M et al. (2016) (1)
Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (1)
Radioiodine therapy a successful tool in treating thyroid cancer. Foreword. (2009) (1)
Incidence of Anti-Thyroid Autoantibodies in Thyroid Cancer Patients (1987) (1)
, Post-surgical thyroid remnant ablation with 131-I therapy in patients with differentiated thyroid cancer (DTC): the role of diagnostic tracer dose (2003) (0)
E. Chester Ridgway, MD, MACP (1942-2014). (2014) (0)
Sperm immaturity in patient with elevated serum gonadotropin levels. (2010) (0)
Table 18-6, Suggested Surgical Procedures in Thyroid Cancer (2013) (0)
Table 18, [– 4. Management of Nodules]. (2012) (0)
Familial papillary thyroid cancer patients display an elevated chromosome fragility characterized by telomeric association and telomere loss (2011) (0)
S 3-SELECTION OF PATIENTS FOR TKI TREATMENT (2014) (0)
A Case of Papillary Thyroid Cancer Without Aggressive Histological Features with a Nodal Metastasis Detected During Follow-Up in a Young Patient (2020) (0)
The Thyroid and its Diseases Chapter 18 , Thyroid Nodules (2016) (0)
THE ROLE OF rhTSH IN THYROID CANCER MANAGEMENT (2007) (0)
Subject Index Vol. 1, 2012 (2013) (0)
Outcome of post Chernobyl papillary thyroid carcinomna treated by surgery , radioiodine and tsh soppressive therapy. (1998) (0)
HUMORAL MARKERS FOR THYROID-CARCINOMA IN CLINICAL-PRACTICE (1991) (0)
Reply to letter: Post-surgical thyroid ablation in intermediate risk-differentiated thyroid cancer patients. (2013) (0)
Medullary Thyroid Cancer and Multiple Endocrine Neoplasia Type 2 (MEN2) (2012) (0)
Telomeric fusions and chromosome instability in familial papillary thyroid cancer patients (2011) (0)
Endopoints for screening thyroid cancer in the Republic of Korea: thyroid specialists’ perspectives (2017) (0)
Chapter 92 – Thyroid Neoplasia (2016) (0)
Molecular analysis of RET and BRAF genes for the presurgical diagnosis of thyroid nodules with indeterminate or inadeguate citology (2006) (0)
Authors’ Response: Should Serum Calcitonin Be Routinely Measured in Patients with Thyroid Nodules—Will the Law Answer before Endocrinologists Do? (2004) (0)
Small neck recurrences in patients with differentiated thyroid cancer (DTC) are accurately diagnosed by the means of ultrasonography (US) and fine needle aspiration biopsy (FNAB) (2003) (0)
NIS mRNA and protein expression in thyroid and non thyroid carcinoma (2003) (0)
Radioiodine Ablation: Current Status (2018) (0)
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes (2004) (0)
Mutations and polymorphism of FSH and LH receptors and sperm quality in men with hypergonadotropic hypogonadism without obvious testicular noxa (2012) (0)
In memoriam Professor Aldo Pinchera (1934–2012) (2012) (0)
Response to Letter to the Editor from Edmundo Avila-Hipolito: “Long-Term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity” (2020) (0)
May HER2 amplification be a molecular marker for a subgroup of familial papillary thyroid cancer (2015) (0)
Ernest L. Mazzaferri, MD, MACP (1936-2013). (2013) (0)
Table 18-9, Radiation Exposure to Personnel During Care of a Patient Who Has Received 100 mCi 131I (2013) (0)
Treatment of toxic multinodular goiter with 131 radioactive iodine - effects in volume reduction, thyroid function and autoimmunity (2017) (0)
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer (1993) (0)
NEW ACHIEVEMENTS IN THE DIAGNOSIS AND TREATMENT OF THYROID NODULES AND CANCER: THE CONTRIBUTION OF THE ENDOCRINOLOGY RESEARCH UNIT OF SIENA (2012) (0)
European Thyroid Association: 38th Annual Meeting, Santiago de Compostela, September 2014: Programme and Abstracts (2014) (0)
After a median follow-up of 3.7 years, patients with low-risk thyroid cancer prepared for postoperative remnant ablation with either L-T 4 withdrawal or rhTSH stimulation have comparable rates of thyroid remnant ablation and tumor recurrence or persistent disease. (2009) (0)
Combination of serum miRNA-190 and -95 is a powerful non-invasive tool in the differential diagnosis of thyroid nodules: preliminary data of a prospective series (2015) (0)
In Memoriam: Ernest L. Mazzaferri MD MACP (1936-2013) (2013) (0)
Differentiated Thyroid Carcinoma of Follicular Origin (2016) (0)
Low-fat butter In diabetic diet counselling may help to reduce the overall fat-consumption of these patients (1991) (0)
Gene-related alterations in four male patients with elevated serum gonadotrophins levels. (2010) (0)
Preferred strategy for postsurgical thyroid ablation in low-risk thyroid cancer. (2018) (0)
Faculty Opinions recommendation of Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. (2010) (0)
[Humoral markers in thyroid carcinoma]. (1986) (0)
Motesanib difosfato nel cancro tiroideo differenziato progressivo (2008) (0)
Radiation-Induced Thyroid Disease (2021) (0)
Subject Index Vol. 4, 2015 (2015) (0)
An ultrastructural study in male smokers affected by varicocele. (2008) (0)
Professor Aldo Pinchera (1934–2012) (2012) (0)
Clinical and biological patterns of bone metastases from differentiated thyroid carcinoma (1989) (0)
Severe hypovitaminosis D and secondary hyperparathyroidism in obese subjects submitted to Roux-en-Y gastric bypass and biliopancreatic diversion (2014) (0)
PRESIDENT: M.D. PAPAGIANNIS VICE PRESIDENTS: F.D. DRAKE and N.S. KARDASHEV (1985) (0)
A Case of Papillary Thyroid Cancer Without Aggressive Histological Features with Nodal Metastases in an Older Patient (2016) (0)
71 Elevated serum tissue polypeptide antigen (TPA) concentration in patients with medullary thyroid carcinoma (MTC) (1983) (0)
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent (2003) (0)
Papillary thyroid cancer : retrospective analysis of 760 patients treated in 20 years period. (1993) (0)
Differentiated (Papillary and Follicular) and Anaplastic Thyroid Carcinoma (2012) (0)
A Case of Papillary Thyroid Cancer Without Aggressive Histological Features with Nodal Metastases Detected During Follow-Up in a Younger Patient (2016) (0)
New ATA recommendation for differentiated thyroid cancer management from the point of view of European endocrinologist (2016) (0)
Diagnosis and Treatment of Hyperthyroidism (2018) (0)
Factors predicting the results of initial treatment (thyroidectomy and thyroid ablation) in patients with differentiated thyroid cancer (2003) (0)
Subject Index Vol. 67, Suppl. 1, 2007 (2007) (0)
S 1-CONTEMPORARY MANAGEMENT OF DIFFERENTIATED THYROID CANCER (2014) (0)
Table 18.5, RARE SYNDROMES WITH HEREDITABLE THYROID TUMORS (NR9) (2013) (0)
Topics Low-Risk Differentiated Thyroid Cancer AME-SIMeL Workshop Laboratory in Endocrine Practice An Update in the Treatment of Acromegaly The Expanding Field of NET: What is the Role of the Endocrinologist? (2006) (0)
Book Review Thyroid Cancer (Endocrine Updates.) Edited by James A. Fagin. 360 pp. Boston, Kluwer Academic, 1998. $189. 0-7923-8326-5 (1999) (0)
Molecular Diagnosis of Thyroid Cancer (2016) (0)
Management of differentiated thyroid cancer (2008) (0)
Table 18-11. I, ndications for Radiation Therapy (2013) (0)
Figure 18-13, Diagnostic sequence and therapeutic decisions in managing a patient with an apparent single nodule of the thyroid. (2016) (0)
Circulating microRNAs may help to differentiate malignant from benign thyroid nodules (2013) (0)
Simian virus 40-like DNA sequences in human thyroid tumors of different histotypes (2003) (0)
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression (2003) (0)
Thyroid Cancer: A Clinical Overview and a Useful Laboratory Manual (2013) (0)
Radioiodine treatment and long-term follow-up of differentiated thyroid cancer (2010) (0)
Objective responses to motesanib are low in patients with medullary thyroid carcinoma, but the disease becomes stable in most patients while receiving the drug (2009) (0)
Contents Vol. 4, 2015 (2015) (0)
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors (2003) (0)
Contents Vol. 1, 2012 (2013) (0)
Table 18-3, Factors to be Considered in Management of Cold Nodules (2016) (0)

This paper list is powered by the following services:

Other Resources About Franco Pacini

en.wikipedia.org

What Schools Are Affiliated With Franco Pacini?

Franco Pacini is affiliated with the following schools:

Image Attributions

Image Source for Franco Pacini